Home > News > Biophan Names John Lanzafame President of New Nanolution Division
September 16th, 2004
Biophan Names John Lanzafame President of New Nanolution Division
Biophan Technologies, Inc., a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner.
As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products.
Industrial Nanotech, Inc. to Publish PCAOB Audited Financials July 31st, 2014
Nanostructured metal-oxide catalyst efficiently converts CO2 to methanol: Highly reactive sites at interface of 2 nanoscale components could help overcome hurdle of using CO2 as a starting point in producing useful products July 31st, 2014
Carnegie Mellon Chemists Create Nanofibers Using Unprecedented New Method July 31st, 2014
Pressure probing potential photoelectronic manufacturing compound July 31st, 2014
ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014
Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014
NSS Pays Tribute to Space Pioneer Frederick I. Ordway III July 7th, 2014
Harris & Harris Group Announces Changes to Its Legal Department June 9th, 2014